



SAN FRANCISCO  
SAFE INJECTION SERVICES TASK FORCE



2017

FINAL REPORT

**SAN FRANCISCO  
DEPARTMENT OF PUBLIC HEALTH**

DIRECTOR OF HEALTH      BARBARA A. GARCIA, MPA



San Francisco Department of Public Health  
101 Grove Street  
San Francisco, CA 94102

For questions related to this report, please e-mail [SIS.Taskforce@sfdph.org](mailto:SIS.Taskforce@sfdph.org)  
Website: [www.sfdph.org/dph/comupg/knowlcol/SISTaskForce](http://www.sfdph.org/dph/comupg/knowlcol/SISTaskForce)

September 2017

# TABLE OF CONTENTS

MESSAGE FROM THE BOARD OF SUPERVISORS PRESIDENT	4
BACKGROUND	6
FACTS ABOUT INJECTION DRUG USE IN SAN FRANCISCO	7
TASK FORCE PROCESS OVERVIEW	8
TASK FORCE RECOMMENDATIONS	9
APPENDICES	14

# MESSAGE FROM THE BOARD OF SUPERVISORS PRESIDENT



Dear Fellow San Franciscans,

Nationwide, the substance abuse epidemic is ravaging communities and taking far too many lives. Sadly, the City of San Francisco is no exception. The Department of Public Health estimates the City is home to some 22,500 people who inject drugs and experiences over 100 injected drug overdose deaths a year. We do not need numbers to tell us how bad the situation is; we see the worsening conditions on our streets every day. You cannot walk from City Hall to Civic Center BART without seeing people shooting up in broad daylight. Orange plastic syringe caps and used needles litter our sidewalks, not only outside of City Hall, but in our neighborhoods. It is unsafe and it is unhealthy. As a caring City, we have an obligation to do better for those in need.

I know the pain of drug abuse all too well. I lost my younger sister to an overdose. I know how difficult it is to get better, and how much help individuals in recovery need every single step of the way. San Francisco has long grappled with how best to serve people like my sister. Yet, too many are still left to wither away on the streets without help, without solutions, and without hope.

With our worsening heroin and opioid epidemic, we need to find real, innovative, and effective ways of helping this population. It is simply not enough to provide voluntary detox services or clean syringe exchanges; we need to provide a robust continuum of care and a welcoming environment for those struggling with drug abuse. We need a one-stop shop of wraparound services that provide hope for a healthier life and opportunities for rehabilitation. Safe Injection Services could potentially provide that opportunity.


Through our Safe Injection Facilities Task Force, we learned that approximately 100 safe injection sites now operate in over 65 cities around the world. No site has experienced an overdose death and many have transitioned thousands of clients into detox services. Studies indicate that these services attract some of the most marginalized people who inject drugs, promote safer injection conditions, reduce overdoses, enhance access to primary care, and reduce public injection and outdoor syringe litter. More importantly, we learned that safe injection services have not increased drug injection, drug trafficking, or crime in the surrounding area.

A 2016 cost-benefit analysis of potential safe injection services in San Francisco found that the City would save \$3.5 million per year if one safe injection program were opened, or \$2.33 for every dollar spent on the services. Meaning, effective, alternative solutions can end up saving taxpayer dollars while also saving lives.

Still, I understand that some community members are unsure about this concept. I do not want safe injection services to make it easier for people to use drugs. I do not want to see neighborhoods divided, as some residents worry safe injection services might draw illegal activity into their community. However, this is too big of an issue for us to rule out any possible solutions. Inaction simply is no longer an option.

Only together can we truly tackle this public health crisis and change the conditions on our streets. In this report, let us study the data, collaborate with one another, and take collective action.

Sincerely,

A handwritten signature in black ink that reads "London Breed". The signature is written in a cursive, flowing style.

London Breed

# BACKGROUND

Ninety-one Americans die every day from an opioid overdose. In fact, opioid overdose deaths have quadrupled over the past 20 years and is now a leading cause of death for adults under age 50.<sup>1</sup> Two million Americans suffer from substance use disorders related to prescription opioids, heroin, and synthetics such as fentanyl. The availability of fentanyl and its poisoning of drug supplies, in particular, poses additional concern due to its ability to heighten the potency and toxic influences of heroin and cocaine when mixed. The majority of overdose deaths from heroin and cocaine test positive for this additive.<sup>2</sup>

Likewise, the rising toll of the nation's opioid epidemic touches San Francisco. In recent years, the city has continued to see overdoses from heroin, methamphetamine, and fentanyl and increasing attention has been placed on public injection drug use. Drug injection is a known risk factor for opioid overdose, and people who inject drugs have health needs that are of particular concern to public health. They are perilously at-risk for unhealthy substance use, the acquisition and transmission of HIV and hepatitis C, serious physical and mental health conditions, and premature death.

Recognizing that addiction is a medical condition, San Francisco operates a continuum of behavioral health care services that range from prevention to treatment services and bases its services in the principles of harm reduction. Safe injection services represent one evidence-based strategy that fits within this harm reduction model.

In April 2017, the Board of Supervisors passed resolution #123-17 (Appendix A), introduced by Board President London Breed, urging the San Francisco Department of Public Health to convene a [Safe Injection Services \(SIS\) Task Force](#) to make recommendations to the Mayor, the Board of Supervisors, and City departments regarding the potential opportunities and obstacles associated with safe injection services, the community need for such services, and the feasibility of opening and operating such services.

In June 2017, DPH released its issue brief (Appendix B) covering topics requested by the Board's resolution, including:


- information on individuals who inject drugs in San Francisco;
- information on supervised injection services in other jurisdictions, including program models, effectiveness, and outcomes;
- potential risks and benefits of supervised injections services; and
- considerations for San Francisco regarding supervised injection services, including legal, community, and operational.

---

<sup>1</sup> <https://www.cdc.gov/drugoverdose/epidemic/index.html>

<sup>2</sup> <http://drugabuse.com/library/is-fentanyl-more-deadly-than-heroin/>

# FACTS ABOUT INJECTION DRUG USE IN SAN FRANCISCO




## PEOPLE WHO INJECT DRUGS ARE AT HIGH RISK FOR...



## HARM REDUCTION METHODS ARE FREE OF JUDGMENT AND DIRECTLY INVOLVE CLIENTS IN SETTING THEIR OWN HEALTH GOALS. SF HAS A COMPREHENSIVE SET OF HARM REDUCTION SERVICES FOR PWID. SOME EXAMPLES ARE:



## WHAT POTENTIAL HEALTH BENEFITS & SAVINGS COULD 1 SAFE INJECTION SERVICES SITE HAVE IN SF EACH YEAR?\*



\*\*Source: Irwin, A., Jozaghi, E., Bluthenthal, R. N., & Kral, A. H. (2017). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, 47(2), 164-184.

# TASK FORCE PROCESS OVERVIEW

Pursuant to resolution #123-17, the Safe Injection Services Task Force was chaired by Barbara A. Garcia, MPA, Director of Health, and consisted of 15 members, appointed to seats identified by resolution.

## SAFE INJECTION SERVICES TASK FORCE MEMBERS

NAME	AFFILIATION
Erick Arguello	Small business owner
Holly Bradford	San Francisco Drug Users Union
Lydia Bransten	Tenderloin Health Improvement Partnership, St. Anthony Foundation
Lt. Troy Dangerfield	San Francisco Police Department
Sam Dodge	Department of Homelessness and Supportive Housing
Mike Discepola	San Francisco AIDS Foundation
Dr. Vitka Eisen	HealthRight 360
Barbara Garcia	Chair, San Francisco Department of Public Health
Dr. Isaac Jackson	Urban Survivors Union
Dr. Alex Kral	RTI International
Wilma Long	Homeless Outreach Team
Dr. Paula Lum	University of California, San Francisco
Laura Thomas	Drug Policy Alliance
Joe Wilson	Hospitality House
Barry Zevin	San Francisco Department of Public Health

The Task Force convened three public meetings, between June 2017 and August 2017, and discussed specific focus areas identified by DPH through the review of published literature and reports: types of safe injection service models, operations, services, location, and siting. The Task Force's commitment, expertise, and contributions to developing this report and its recommendations are deeply appreciated and indispensable.

In addition to Task Force members' expertise, DPH sought to include a diverse set of perspectives from an array of San Franciscans that included:

- a public online survey of business owners, neighborhood groups, and residents
- focus groups with business owners, neighborhood groups, and residents
- a survey conducted by HealthRight 360 with people in early recovery
- a community survey with people who inject drugs
- public comment at Task Force meetings

A summary of the surveys and focus group tools is included in Appendix C. More information on the Task Force's meetings and materials can be found at the [Safe Injection Services Task Force](#) webpage.



# TASK FORCE RECOMMENDATIONS

The following recommendations are the culmination of the Task Force’s work and are informed by their diverse expertise, the local perspectives of people who inject drugs and the public, and findings from independent research around the world. The recommendations are intended to provide guidelines for the purpose of planning and development, and they are not designed to be mutually exclusive in supporting decision-making and implementation. They are organized by category below:

## **1. Support creation of safe injection services in San Francisco.**

The Task Force’s overarching recommendation is to support the operation of safe injection services in San Francisco. The rise in public injection drug use and its harmful public health and safety outcomes has long reached critical mass in the City, and this urgency is commonly felt by members of the Task Force and San Francisco residents alike. Research consistently demonstrates that safe injection services are an evidenced-based harm reduction strategy that can address this public health issue.

## PROGRAM PLANNING & MANAGEMENT

## **2. Recognize legal and real estate barriers to operating safe injection services and devise necessary contingency plans.**

The possession of controlled substances – unless the possession is with the prescription of a licensed health professional – is prohibited by both state and federal law. State and federal law also prohibits building owners and operators from allowing the manufacture, storage, or distribution of a controlled substance, and criminal and civil penalties may be imposed on all parties engaged in the property. San Francisco must continue advocating for the passage of Assembly Bill 186 during the 2018 legislative session – which would allow some counties to operate safe injection sites according to specific requirements. In order to proceed with operating safe injection services, San Francisco must be deliberate in formulating a way forward for local agencies, community organizations, and building owners that includes local protections and procedures to respond to potential legal repercussions.

## **3. Conduct an assessment to determine the optimal service scale, site requirements, capacity, work flow, hours of operation, and staffing mix.**

In order to properly implement safe injection services in a potential area, a thorough assessment must be completed to gauge the demand for services, needed capacity, and necessary operational components to ready a site and staff to operate successfully. Preparing the right scope and size of a site is essential to supporting

people who inject drugs, managing client flow, and optimizing the benefits to the surrounding area.

**4. Design safe injection services as a safe, clean, and welcoming space for people who inject drugs.**

Safe injection services are an opportunity to affirm the humanity and dignity of people who inject drugs, and the space must reflect these values in providing compassionate care and services. A hospitable and hygienic place that reduces the stigma and inherent dangers of public drug use will be more successful in building trust, creating engagement, disseminating safer drug use practices, linking persons who use drugs to treatment, and improving health outcomes.

**5. Pilot small-scale integrated safe injection sites that can be flexible to emerging needs.**

Allow for agility and flexibility at the onset of assessing and planning for a safe injection site. While a site may begin operating at a smaller scale, anticipate opportunities to modify the scope and size of a site depending on emerging trends and the needs of people who inject drugs and stakeholders in the surrounding community.

**6. Ensure planning and implementation of safe injection services integrates clear program goals and metrics, including defined practices for data collection, monitoring, and evaluation to facilitate ongoing quality improvement processes.**

Develop an evaluation plan with clear goals and objectives to measure the success of any safe injection services. It is critical to build in reliable data collection procedures that support active monitoring, evaluation and quality improvement efforts. Maintain transparency with the public about the progress and impact of safe injection services in order to address concerns that may arise.

## MODEL

**7. Support an integrated model that includes on-site services and linkages to other services.**

An integrated model is generally the best fit for San Francisco's population and existing system of care. It is consistent with DPH's overall model and approach to connected services which can optimize access to other important health and social services, linkages to substance use treatment services, and coordinating care for persons with complex medical conditions.

#### **8. Incorporate a peer component in the staffing model.**

Research and feedback from people who inject drugs demonstrate the value of incorporating people who currently or formerly inject drugs in staffing safe injection services. In addition to expressed preferences by some people who inject drugs, peer staff are uniquely positioned to enhance the benefits of safe injection services by engaging those who encounter similar social and structural barriers to accessing sanctioned services. Harnessing their relationships with people who inject drugs and familiarity with experiences represents one of the most promising ways to leverage peer networks and community expertise in addressing opioid drug use.

#### **9. Consider expanding the types of drug consumption allowed on-site.**

Individuals that consume drugs by other routes experience health disparities similar to people who inject drugs. While injection drug use is the primary focus at this time, future considerations should explore expanding the types of drug consumption allowed at harm reduction service sites.

## LOCATION

#### **10. Operate multiple sites throughout San Francisco.**

San Francisco would be best served by operating multiple safe injection service sites in neighborhoods where public injection drug use, overdoses, and improperly discarded syringes most often occur. Having various sites would enable a distribution of capacity and greater penetration of services where people who inject drugs are most likely to be.

#### **11. Locate safe injection services where drug use most often occurs.**

Safe injection services should be located near where public injection drug use most often occurs to best ensure they are used by the target population. Locating services in these areas can offer the greatest benefit to the surrounding communities by preventing improperly discarded needles, public overdoses, and other health and safety advantages.

#### **12. Locate safe injection services where existing services are delivered to people who inject drugs.**

Operating safe injection services where people who inject drugs already receive services can better ensure that safe injection services are administered by service providers that have developed trusted relationships with people who inject drugs. This level of engagement can increase the likelihood that safe injection services are utilized and achieve success in linking people who inject drugs with treatment and other services.

## COMMUNITY ENGAGEMENT & EDUCATION

### **13. Engage the public throughout the planning process to optimize the usage and benefits of safe injection services to the surrounding community, including:**

- **people who inject drugs**
- **stakeholders from potential neighborhoods**
- **business owners**
- **neighborhood groups**
- **San Francisco residents**

Planning for safe injection services must acknowledge a diverse set of community opinions. It is crucial to engage residents and businesses in prospective neighborhoods throughout the planning process to develop common goals and objectives, troubleshoot concerns, and establish feedback loops for evaluation. Mechanisms for ongoing public input, outreach, and education are vital to ensuring that the surrounding community has a voice and constructive role in designing and supporting the site. Importantly, the perspectives of people who inject drugs must be incorporated to ensure the services are used and accomplish their purpose.

### **14. Engage law enforcement, probation, and parole agencies to determine public safety priorities and strategies.**

These agencies must be fully engaged at all stages of planning, implementation, and evaluation to arrive at the careful balance of securing public safety while providing safe injection services. Their involvement is critical in shaping the successful integration of safe injection services in various communities.

### **15. Partner with other city agencies and community organizations to develop collaborative, comprehensive, and sustainable harm reduction strategies.**

To meaningfully address injection drug use in San Francisco and the impairment and distress that results requires robust and earnest collaboration across government agencies and community-based organizations. It is key that all parties commit to: sustaining funding and resources; cultivating cooperative and accountable relationships; establishing clear roles and responsibilities; and equipping their personnel with complementary, appropriate, and ongoing training.

### **16. Develop a public-focused central information source and education campaign on the benefits of safe injection services that also seeks to address stigma toward people who use drugs.**

Commit resources to outreach and educating the public on the purpose and goals of safe injection services, including their role as part of San Francisco's continuum of harm reduction services and as a pathway to recovery for those seeking treatment. Such a campaign can serve to reduce stigma toward people who use drugs and facilitate engagement with communities to foster a supportive environment for a successful program. The campaign should engage televised, audio, online, and social media formats, and leverage presentations at community meetings, social service organizations, neighborhood associations, and other local gatherings. The City should

establish a corresponding publicly-accessible and central information source that provides accurate and current information on harm reduction and substance use treatment services.

## SPECIAL POPULATIONS

### **17. Identify and commit resources for special populations that face health disparities, barriers to services, and/or risk for experiencing violence related to drug use, including, but not limited to:**

- **people of color**
- **women**
- **transitional age youth**
- **people experiencing homelessness**
- **LGBTQI**
- **people in the sex trade**
- **recently/formerly incarcerated people**

It is important to identify the barriers and threats that members of many communities regularly experience that lead to heightened risks for injury and marginalization. Moreover, it is consistent with San Francisco's enduring history of providing compassionate care and services to extend culturally-appropriate and thoughtful interventions to people who inject drugs who are most vulnerable to harm.

# APPENDICES

- A.** BOARD OF SUPERVISORS RESOLUTION: 123-17
- B.** ISSUE BRIEF
- C.** SUMMARY OF LOCAL SURVEY & INTERVIEW TOOLS

BOARD of SUPERVISORS



City Hall  
1 Dr. Carlton B. Goodlett Place, Room 244  
San Francisco 94102-4689  
Tel. No. 554-5184  
Fax No. 554-5163  
TDD/TTY No. 544-5227


---

---

MEMORANDUM

---

---

Date: April 24, 2017  
To: Barbara A. Garcia, Director, Department of Public Health  
From:  Angela Calvillo, Clerk of the Board, Board of Supervisors  
Subject: Urging the Department of Public Health to Convene a Safe Injection Services Task Force (File No. 170353)

---

On April 11, 2017, the Board of Supervisors adopted Resolution No. 123-17, sponsored by Supervisor London Breed (File No. 170353, Urging the Department of Public Health to Convene a Safe Injection Services Task Force); enacted on April 21, 2017.

Please find the attached courtesy copy of the Resolution for the Department of Public Health's information and consideration.

If you have any questions or concerns, please contact the Office of the Clerk of the Board at (415) 554-5184.

c: Board President Breed; Supervisors Sheehy, Ronen, Kim  
Department of Public Health, Chief Financial Officer, Greg Wagner  
Department of Public Health, Deputy Director of Policy and Planning, Colleen Chawla

1 [Urging the Department of Public Health to Convene a Safe Injection Services Task Force]

2  
3 **Resolution urging the Department of Public Health to convene a Safe Injection Services**  
4 **Task Force to make recommendations to the Mayor, the Board of Supervisors, and City**  
5 **departments regarding Safe Injection Services.**

6  
7 WHEREAS, San Francisco has an estimated 22,500 people who inject drugs (PWID)  
8 according to the City's Department of Public Health; and

9 WHEREAS, Injection drug use in San Francisco is responsible for approximately 100  
10 deaths a year from overdoses and continued health risks for thousands; and

11 WHEREAS, deaths are often concentrated in high-poverty areas of San Francisco and  
12 disproportionately affect African Americans,

13 WHEREAS, The public, unsupervised use of injected drugs creates dangerous and  
14 alarming conditions in public spaces for residents, visitors and PWID themselves; and

15 WHEREAS, As a city, San Francisco must acknowledge that more must be done to  
16 promote public safety and that the public health risks from inaction are beyond what is  
17 tolerable for a caring city, and

18 WHEREAS, On September 5, 2000, the San Francisco Health Commission  
19 unanimously passed a resolution adopting a Harm Reduction Policy for the Department of  
20 Public Health, and

21 WHEREAS, Harm reduction is a public health philosophy that offers multiple, non-  
22 judgmental approaches to meet individuals "where they are" and assist them in their  
23 movement toward better health, and.



1           WHEREAS, The harm reduction model promotes methods of reducing the physical,  
2 social, emotional, and economic harms associated with drug and alcohol use and other  
3 harmful behaviors on individuals and their community, and

4           WHEREAS, Safe Injection Services (SIS), also known as Supervised Consumption  
5 Services, are an evidence-based harm reduction strategy that allows individuals to inject or  
6 consume illicit drugs in a hygienic environment under the supervision of trained staff and have  
7 opportunities to engage in other health and social services; and

8           WHEREAS, SIS, embedded in a harm reduction-oriented system of care and support  
9 services, has the potential to address many of the concerns and issues listed above and is  
10 worth evaluating for their potential costs and benefits;

11           WHEREAS, SIS reduce overdose deaths for entire neighborhoods around the sites,  
12 and there has never been a recorded overdose death in any of the nearly 100 sites around  
13 the world, despite many overdoses in those sites; and

14           WHEREAS, SIS attract and retain a population of people who inject drugs and are at a  
15 high risk for infectious disease and overdose, who are more likely to be homeless or  
16 marginally housed, and who are at heightened risk for violence and trauma; and

17           WHEREAS, a 2010 study (Kral et. al.) entitled "Acceptability of a Safe Injection Facility  
18 among Injection Drug Users in San Francisco" showed that 85% of the 602 people who inject  
19 drugs that were surveyed said that they would use safe injection services, three quarters of  
20 whom would use it at least three days per week; and

21           WHEREAS, SIS provide multiple health benefits, including reducing HIV and hepatitis  
22 C risk behavior (i.e. syringe sharing); reducing the prevalence and harms of bacterial  
23 infections; saving costs due to a reduction in disease, overdose deaths, and need for  
24 emergency medical services; providing safer injection education, subsequently increasing  
25 safer injecting practices; and increasing linkage to medical and social services; and

1           WHEREAS, A 2014 systematic review concluded that, "All studies converged to find  
2 that SIFs [Safe Injection Facilities] were efficacious in attracting the most marginalized people  
3 who inject drugs, promoting safer injection conditions, enhancing access to primary health  
4 care, and reducing the overdose frequency. SIFs were not found to increase drug injecting,  
5 drug trafficking or crime in the surrounding environments. SIFs were found to be associated  
6 with reduced levels of public drug injections and dropped syringes;" and

7           WHEREAS, A cost-benefit analysis of potential SIS in San Francisco (Irwin et al.,  
8 2016) found that the City would save \$3.5 million per year if one SIS program were opened, or  
9 \$2.33 for every dollar spent on the services; and

10           WHEREAS, SIS have been supported by the Mayor's Hepatitis C Task Force in 2011,  
11 the HIV Prevention Planning Council and HIV Health Services Planning Councils in 2015, and  
12 the Human Rights Commission's community report on their hearing on the war on drugs in  
13 2014; now, therefore, be it

14           WHEREAS, The Mayor raised the issue in his 2017 State of the City speech, saying, "I  
15 will continue to learn about the effectiveness of safe injection facilities. We must thoroughly  
16 assess whether the public health and safety benefits outweigh any negative impacts"; and

17           WHEREAS, there is momentum at the state level to address issues around injected  
18 drug use with California Assembly Bill 186, introduced by Assemblymember Susan  
19 Talamantes Eggman and co-authored by Senator Scott Wiener and Assemblymember Laura  
20 Friedman, would further allow localities such as San Francisco to explore the possibility of  
21 such services and enhance legal protections for the operation and use of such services; and

22           WHEREAS, Other cities in the United States are actively evaluating the impact of SIS,  
23 including Seattle, which has already decided to move forward with opening two sites,  
24 Baltimore, Boston, Denver, Ithaca, New York City, Philadelphia, and Portland; and

1           WHEREAS, There are approximately 100 SIS currently operating in over 65 cities  
2 around the world in ten countries (Switzerland, Germany, the Netherlands, Norway,  
3 Luxembourg, Spain, Denmark, France, Australia, and Canada); now, therefore be it

4           RESOLVED, That the Board of Supervisors urges the Department of Public Health to  
5 convene a task force – and the City Attorney to advise the Department of Public Health in this  
6 effort for the purpose of – advising the Mayor, the Board of Supervisors, and relevant City  
7 departments regarding the possibility of operating safe injection services in the City; and, be it

8           FURTHER RESOLVED, That Board recommends that the task force consist of 15 or  
9 fewer members chosen by the Department of Health from the following categories: (1) an  
10 employee of the Department of Public Health designated by the Director of Health; (2) an  
11 employee of the Police Department designated by the Chief of Police; (2) an employee of the  
12 Department of Homelessness and Supportive Housing designated by the head of that  
13 department; (4) a researcher with expertise in safe injection services and drug user health; (5)  
14 a researcher or medical doctor with expertise in substance use treatment; (6) a homelessness  
15 advocate or service provider; (7) a representative of a drug user advocacy organization; (8) a  
16 representative of a harm reduction organization; (9) a representative of a drug policy  
17 organization, with expertise in safe injection services advocacy; (10) a representative of a  
18 substance use treatment organization; (11) a small business owner in a neighborhood  
19 affected by public drug use; (12) a medical clinician who works with people who use drugs;  
20 (13) a representative of the Tenderloin Health Improvement Project; (14) a representative of  
21 the HIV Community Planning Council Substance Use Work Group; and (15) a representative  
22 of the recovery community; and, be it

23           FURTHER RESOLVED, That the Board urges the Department of Public Health to  
24 convene the task force within 30 days of the enactment of this resolution and to submit to the  
25 task force a report regarding the questions that the task force should investigate, including the

1 potential opportunities and obstacles associated with safe injection services, the community  
2 need for such services, and the feasibility of providing such services; and, be it

3 FURTHER RESOLVED, That the Board urges the task force to hold a series of public  
4 meetings to solicit input from the public and from stakeholder groups, and to submit a report to  
5 the Mayor and the Board of Supervisors within three months of its initial meeting; and, be it

6 FURTHER RESOLVED, That the Board urges the task force to include the following  
7 information in its report: (1) Information on individuals who inject drugs in San Francisco, (2)  
8 Information on safe injection services in other jurisdictions, including program models,  
9 effectiveness, outcomes, (3) Potential risks and benefits of safe injection services, (4)  
10 Considerations for San Francisco regarding safe injection services, including legal,  
11 community, and operational considerations, and (5) Policy recommendations for  
12 consideration.



City and County of San Francisco  
Tails  
Resolution

City Hall  
1 Dr. Carlton B. Goodlett Place  
San Francisco, CA 94102-4689

File Number: 170353

Date Passed: April 11, 2017


Resolution urging the Department of Public Health to convene a Safe Injection Services Task Force to make recommendations to the Mayor, the Board of Supervisors, and City departments regarding safe injection services.

April 11, 2017 Board of Supervisors - ADOPTED

Ayes: 11 - Breed, Cohen, Farrell, Fewer, Kim, Peskin, Ronen, Safai, Sheehy, Tang and Yee

File No. 170353


I hereby certify that the foregoing Resolution was ADOPTED on 4/11/2017 by the Board of Supervisors of the City and County of San Francisco.

  
\_\_\_\_\_  
Angela Calvillo  
Clerk of the Board

\_\_\_\_\_  
Unsigned  
Mayor


\_\_\_\_\_  
4/21/17  
Date Approved

I hereby certify that the foregoing resolution, not being signed by the Mayor within the time limit as set forth in Section 3.103 of the Charter, or time waived pursuant to Board Rule 2.14.2, became effective without his approval in accordance with the provision of said Section 3.103 of the Charter or Board Rule 2.14.2.

  
\_\_\_\_\_  
for Angela Calvillo  
Clerk of the Board

\_\_\_\_\_  
4/21/17  
Date

# APPENDIX B: HARM REDUCTION SERVICES IN SAN FRANCISCO



## ISSUE BRIEF

JUNE 2017



## SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

DIRECTOR OF HEALTH

BARBARA A. GARCIA, MPA

HEALTH OFFICER  
DIRECTOR, POPULATION HEALTH DIVISION

TOMÁS J. ARAGÓN, MD, DRPH



San Francisco Department of Public Health  
101 Grove Street  
San Francisco, CA 94102

For questions related to this report, please contact  
Israel Nieves-Rivera  
Director, Office of Equity & Quality Improvement  
Population Health Division  
Email: [SIS.Taskforce@sfdph.org](mailto:SIS.Taskforce@sfdph.org)  
Website: [www.sfdph.org/dph/comupg/knowlcol/SISTaskForce](http://www.sfdph.org/dph/comupg/knowlcol/SISTaskForce)

June 2017

# TABLE OF CONTENTS

ACRONYMS	4
EXECUTIVE SUMMARY	5
SECTION I: FRAMING THE ISSUE	7
SECTION II: INFORMATION ON PEOPLE WHO INJECT DRUGS IN SAN FRANCISCO	8
SECTION III: PUBLIC HEALTH CONCERNS AMONG PWID	10
SECTION IV: HARM REDUCTION IN SAN FRANCISCO	13
SECTION V: ABOUT SAFE INJECTION SERVICES	15
SECTION VI: POTENTIAL BENEFITS AND RISKS OF SAFE INJECTION SERVICES	22
SECTION VII: CONSIDERATIONS FOR SAN FRANCISCO REGARDING SAFE INJECTION SERVICES	25
SECTION VIII: CONCLUSION	27
ENDNOTES	28



# ACRYONYMS

<b>ARCHES</b>	Applied Research, Community Health Epidemiology & Surveillance
<b>CDC</b>	Centers for Disease Control and Prevention
<b>CSA</b>	Controlled Substance Act
<b>DCR</b>	Drug Consumption Rooms
<b>DOPE</b>	Drug Overdose Prevention and Education
<b>HCV</b>	Hepatitis C Virus
<b>HIV</b>	Human Immunodeficiency Virus
<b>MSM</b>	Males who have Sex with Males
<b>NHBS</b>	National HIV Behavioral Surveillance
<b>PWID</b>	People Who Inject Drugs
<b>SFDPH</b>	San Francisco Department of Health
<b>SCF</b>	Safe Consumption Facilities
<b>SCS</b>	Supervised Consumption Services
<b>SIF</b>	Supervised Injection Facilities
<b>SIS</b>	Safe Injection Services
<b>US</b>	United States
<b>USC</b>	Unites States Code (USC)

## HARM REDUCTION SERVICES IN SAN FRANCISCO

### SECTION I: FRAMING THE ISSUE

There are an estimated 22,500 people who inject drugs (PWID) in San Francisco. Between 2006 and 2014, opioid overdose deaths in San Francisco remained relatively constant between 110 to 120 per year. In 2015, saw a decline with 98 deaths due to opioids (prescription and heroin) and 81 deaths due to stimulants. Approximately 69 percent of PWID surveyed over a six-month period reported living on the street, using homeless shelters or living in single room occupancy (SRO) hotels. The lack of stable housing opportunities has increased the public consumption of drugs and increased the nuisance of publicly discarded syringes.

Part of the continuum of harm reduction services for PWID, safe injection services (SIS) allow individuals to inject illicit drugs in a hygienic environment under the supervision of trained staff and have opportunities to engage in other health and social services. In April 2017, the Board of Supervisors passed resolution #123-17, introduced by Board President London Breed, urging the San Francisco Department of Public Health (SFDPH) to convene a Safe Injection Services (SIS) Task Force to make recommendations to the Mayor, the Board of Supervisors, and City departments regarding the potential opportunities and obstacles associated with safe injection facilities, the community need for such facilities, and the feasibility of opening and operating such facilities.

### SECTION II: INFORMATION ON PEOPLE WHO INJECT DRUGS IN SAN FRANCISCO

#### DEMOGRAPHICS & GEOGRAPHY

SFDPH estimates the local population of PWID at approximately 22,500 individuals. In 2015, the majority of PWID were male (71.4%), ages 41-60 (55.1%), and primarily injecting heroin (49.5%) and methamphetamine (33.8%) The population most often resided in Tenderloin (31%), South of Market (24%), Mission (9%), and Bayview-Hunters Point (8%) neighborhoods.

### SECTION III: PUBLIC HEALTH CONCERNS AMONG PWID

PWID have multiple health needs that must be addressed in order to support their health and well-being, including how the use of drugs can lead to substance use disorder, transmission and acquisition to blood borne pathogens, exposure to communicable diseases and other unsanitary conditions, and overdose death.

#### SUBSTANCE USE DISORDER (SUD)

Many persons with SUD suffer from the disease of addiction which is a medical disorder that is a primary, chronic disease of brain reward, motivation, memory and related circuitry; reflected in an individual pathologically; pursuing reward and/or relief by substance use and other behaviors; characterized by inability to consistently abstain, impairment in behavioral control, craving,

diminished recognition of significant problems with one's behaviors and interpersonal relationships, and a dysfunctional emotional response; and often characterized by cycles of relapse and remission.

#### HUMAN IMMUNODEFICIENCY VIRUS (HIV)

In San Francisco, PWID and PWID who are homeless: account for 21 percent of people living with HIV; report injecting drugs (8.1%) in the prior 12 months among patients receiving HIV care; are less likely to be virally suppressed and more likely to transmit HIV; and have the lowest five-year survival rate of those living with HIV.

#### HEPATITIS C VIRUS (HCV)

In San Francisco, there are an estimated 23,000 residents with antibodies to HCV, and, approximately, 70 percent of active HCV infections are among PWID.

#### OVERDOSE

Recently in San Francisco, deaths due to heroin and methamphetamine have been increasing, and the largest percentage of deaths (approximately 33%) occurred in Tenderloin and South of Market. Most deaths occurred in single room occupancy hotel units where people tend to use in isolated settings.

### SECTION IV: HARM REDUCTION IN SAN FRANCISCO

San Francisco's continuum of substance use disorder services are based on the principles of harm reduction. Harm reduction is a public health philosophy that promotes methods of reducing the physical, social, emotional, and economic harms associated with drug and alcohol use and other harmful behaviors that impact individuals and their community. Harm reduction methods are free of judgment and directly involve clients in setting their own health goals.

The City formally sanctioned syringe access in 1993, and began funding programs as an essential structural component of HIV prevention services. A local study showed that San Francisco syringe programs reduced drug use and drug-related harms without increasing drug use among PWIDs. Additional studies have also found use of syringe services to be associated with reduced syringe sharing and other injection-related risk reduction behaviors.

Today, methadone and buprenorphine (medication-assisted treatment for opioid addiction) are available on demand for people who want to stabilize their illness. Additionally, the Homeless Outreach Team has embedded street medicine specialists who initiate medication-assisted treatment and treat abscesses and injection wounds. All of these programs provide linkages to medical care and treatment services. In 2003, San Francisco was the first city in the US to make naloxone readily available to members of the public. This service has drastically reduced the number of overdose deaths from injection drug use, and 2016 saw 877 reported reversals of overdoses.

## SECTION V: ABOUT SAFE INJECTION SERVICES

### BACKGROUND

Safe injection services are a part of the continuum of harm reduction services that were developed to promote safer drug injection practices, enhance health-related behaviors among PWID, and connect PWID with external health and social services. Globally, these facilities are professionally supervised facilities where drug users can consume drugs in safer conditions.

### SAFE INJECTION SERVICES AROUND THE WORLD

Data are available on 10 countries that provide SIS:

- Five countries (Spain, Switzerland, Germany, the Netherlands, and Denmark) reported having multiple locations (ranging from five to 37) with varying services at each. Spain and Denmark each reported having one mobile drug consumption room in addition to fixed sites.
- Five countries (Australia, Canada, Luxemburg, Norway, and France) reported having only one location. Australia, Luxemburg, and Norway restrict eligibility to person 18 years or older. All five are in fixed locations using an integrated model with a mix of services and linkages to other community services.

In January 2017, officials in Seattle and King County, Washington approved opening safe consumption facilities sites in their jurisdiction and developed a document entitled *Safe Consumption Facilities: Evidence and Models*. The document reviews three different services delivery models (integrated, specialized, and mobile) that differ in staffing, size, and organizational structure with features and staffing levels based on local circumstances.

## SECTION VI: POTENTIAL BENEFITS AND RISKS OF SAFE INJECTION SERVICES

### BENEFITS

Studies indicate that SIS are associated with an array of benefits, including: attracting the most marginalized PWID; promoting safer injection conditions; enhancing access to primary health care and other services; reducing the overdose frequency; reducing public drug injections; and reducing dropped syringes and hazardous litter

SIS are not found to increase drug injection, drug trafficking, or crime in the surrounding environments. Implementing SIS would not necessarily require any significant or fundamental changes in public policy or law. Additionally, they require the same working agreements with social service providers and the police that needle exchange, street-outreach, drug treatment and similar health programs for injectors already receive.

### COST BENEFIT

In 2017, Amos Irwin and colleagues published an article titled *A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA*. At an estimated cost of \$2.6 million annually to operate a facility based on the Vancouver program InSITE, the researchers found that each dollar spent on SIS would generate \$2.33 in savings, for total annual net savings of \$3.5 million for a single 13-booth SIS site. They further found that a SIS site in San Francisco would not only be a cost-effective intervention but also a significant boost to the public health system.

### RISKS

#### *Federal and State Controlled Substances Laws*

Currently, the possession of controlled substances, without the prescription of a licensed health professional, is prohibited by both state and federal law, in addition to prohibitions on building owners and operators from allowing the manufacturing, storing, or distributing controlled substances. On May 12, 2017, Attorney General Jeff Sessions directed all federal prosecutors to pursue the maximum penalties under the law for all crimes, including mandatory minimum sentences.

#### *Government Contracting Requirements*

Another risk is the standard boiler plate language used in federal, state and local funding agreements where contractors and subcontractors agree to maintain a drug free work place.

## SECTION VII: CONSIDERATIONS FOR SAN FRANCISCO REGARDING SAFE INJECTION SERVICES

### LOCATION

A key consideration for implementing SIS is identifying locations where PWID already access services. Research conducted in San Francisco in 2008 found that 85 percent of study participants reported they would use SIS if they were convenient for them. Focusing on existing locations already serving PWID increases the likelihood that PWID will use SIS. The survey further found that nearly three-quarters of respondents (72%) would be willing to walk up to 20 minutes to a SIS site.

### COMMUNITY

Engagement of the communities surrounding any proposed SIS location will be critical. One study that conducted in-depth interviews with 20 sampled stakeholders found concern about the implementation of SIS, including how they would impact a community struggling with safety and cleanliness, and the efficacy of harm reduction strategies to address drug use. Still, they were open to dialogue about how a SIS site might support neighborhood goals; and they stressed the importance of respect and collaboration between stakeholders and those potentially implementing SIS.

### PROGRAM DESIGN

The programmatic design of any contemplated SIS location would need to ensure acceptability by and support of PWID. Identifying locations where PWID are already being served, as noted above, is one key element of program design. Additionally, the presence of other onsite support services, the accessibility of services, and the structure of the rules governing the program would also be critical.

### LEGAL

It will be important for any proposed SIS provider to fully understand the associated legal risks.

# SECTION I

## FRAMING THE ISSUE

---

There are an estimated 22,500 people who inject drugs (PWID) in San Francisco. Between 2006 and 2014, opioid overdose deaths in San Francisco remained relatively constant at around 110 to 120 per year. In 2015, the City saw a decline with 98 deaths due to opioids (prescription and heroin) and 81 deaths due to stimulants. Approximately 69 percent of PWID surveyed over a six-month period reported living on the street, using homeless shelters or living in single room occupancy (SRO) hotels.<sup>1</sup> The lack of stable housing opportunities has increased the public consumption of drugs and increased the nuisance of publicly discarded syringes.

Part of the continuum of harm reduction services for PWID, safe injection services (SIS) allow individuals to inject illicit drugs in a hygienic environment under the supervision of trained staff and have opportunities to engage in other health and social services. In April 2017, the Board of Supervisors passed resolution #123-17, introduced by Board President London Breed, urging the San Francisco Department of Public Health (SFDPH) to convene a Safe Injection Services (SIS) Task Force to make recommendations to the Mayor, the Board of Supervisors, and City departments regarding the potential opportunities and obstacles associated with safe injection facilities, the community need for such facilities, and the feasibility of opening and operating such facilities. The resolution requested that the report included the following information:

1. Information on individuals who inject drugs in San Francisco;
2. Information on supervised injection services in other jurisdictions, including program models, effectiveness, and outcomes;
3. Potential risks and benefits of supervised injections services;
4. Considerations for San Francisco regarding supervised injection services, including legal, community, and operational; and
5. Policy recommendations for consideration.

This report has been compiled in response to this request. The health department recognized that nationally and globally there are many reports and articles that have reviewed these key considerations. This report draws on this expertise and is a summary of key findings that San Francisco can use to have a deliberative dialogue regarding this topic.

# SECTION II

## INFORMATION ON PEOPLE WHO INJECT DRUGS IN SAN FRANCISCO

### DEMOGRAPHICS

SFDPH estimates the local population of PWID at approximately 22,500 individuals.<sup>2</sup> Using data from National HIV Behavioral Surveillance (NHBS), which conducts interviews with PWID due to their increased risk for HIV, Table 1 provides data on PWID in San Francisco. In **2015, the majority of PWID were male (71.4%), ages 41-60 (55.1%), and primarily injected heroin (49.5%) and methamphetamine (33.8%).**

**TABLE 1: DEMOGRAPHICS AND OTHER DATA ON PEOPLE WHO INJECT DRUGS, NATIONAL HIV BEHAVIORAL SURVEILLANCE, SAN FRANCISCO, 2005-2015**

	2005 n = 565 N (%)	2009 n = 535 N (%)	2012 n = 570 N (%)	2015 n = 479 N (%)
<b>Age</b>				
<=20	2 (0.4)	0 (0.0)	3 (0.5)	1 (0.2)
21-30	29 (5.1)	37 (6.9)	38 (6.7)	62 (12.9)
31-40	126 (22.3)	88 (16.5)	74 (13.0)	103 (21.5)
41-50	224 (39.7)	182 (34.0)	184 (32.3)	118 (24.6)
51-60	157 (27.8)	191 (35.7)	215 (37.7)	146 (30.5)
61-70	26 (4.6)	35 (6.5)	56 (9.8)	45 (9.4)
70+	1 (0.2)	2 (0.4)	0 (0.0)	2 (0.4)
<b>Gender</b>				
Male	411 (72.7)	355 (66.4)	396 (69.5)	342 (71.4)
Female	142 (25.1)	165 (30.8)	166 (29.1)	131 (27.4)
Other	12 (2.1)	15 (2.8)	8 (1.4)	6 (1.3)
<b>Race/Ethnicity</b>				
White	231 (40.9)	227 (42.4)	207 (36.3)	226 (41.2)
Black	191 (33.8)	170 (31.8)	229 (40.2)	131 (27.4)
Latino	58 (10.3)	74 (13.8)	45 (7.9)	66 (13.8)
Mixed/other	85 (15.0)	64 (12.0)	89 (15.6)	56 (11.7)
<b>Education</b>				
Never attended school	2 (0.4)	1 (0.2)	1 (0.2)	0
Grades 1 through 8	34 (6.0)	18 (3.4)	23 (4.4)	20 (4.2)
Grades 9 through 11	128 (22.7)	112 (20.9)	117 (20.5)	96 (20.1)
Grade 12 or GED	242 (42.8)	219 (40.9)	222 (39.0)	187 (39.1)
Some College	130 (23.0)	152 (28.4)	170 (29.8)	152 (31.8)
College	20 (3.5)	27 (5.1)	25 (4.4)	12 (2.5)
Post-Graduate	9 (1.6)	6 (1.1)	12 (2.1)	11 (2.3)
<b>Income</b>				
\$0 – 9,999	426 (75.4)	265 (49.5)	229 (40.2)	195 (40.8)
\$10,000 – 29,999	109 (19.3)	236 (44.1)	286 (50.2)	234 (48.9)
\$30,000 – 49,999	13 (2.3)	25 (4.7)	29 (5.1)	17 (3.5)
\$50,000 – 74,999	6 (1.1)	6 (1.1)	15 (2.6)	10 (2.1)
\$75,000+	4 (0.7)	3 (0.6)	9 (1.6)	8 (1.7)

**TABLE 1: DEMOGRAPHICS AND OTHER DATA ON PEOPLE WHO INJECT DRUGS, NATIONAL HIV BEHAVIORAL SURVEILLANCE, SAN FRANCISCO, 2005-2015**


	2005 n = 565 N (%)	2009 n = 535 N (%)	2012 n = 570 N (%)	2015 n = 479 N (%)
<b>Homeless, homeless shelter, or SRO in past 6 months</b>	319 (56.5)	299 (55.9)	345 (60.5)	327 (68.6)
<b>Primary drug injected**</b>				
Heroin	427 (75.6)	379 (70.8)	350 (61.4)	237 (49.5)
Cocaine	148 (26.2)	9 (1.7)	10 (1.8)	1 (0.2)
Speedball	202 (35.8)	27 (5.1)	37 (6.5)	37 (7.7)
Crack	46 (8.1)	1 (0.2)	2 (0.4)	2 (0.4)
Methamphetamine	260 (46.0)	103 (19.3)	157 (27.5)	162 (33.8)
Other	38 (6.7)	16 (3.0)	14 (2.5)	40 (8.3)

\*\*Drug injected was asked as “check all” for 2005 and only “primary drug” for 2009/2012/2015.

## GEOGRAPHIC LOCATION

The NBHS data also show that PWID reside primarily in the **94102 (31%)** and **94103 (24%)** zip codes. The next highest zip codes are 94110 at 9 percent followed by 94124 at 8 percent. Figure 1 shows the estimated percent of population size by San Francisco zip codes.

**FIGURE 1: IDU POPULATION SIZE (2015)**



# SECTION III

## PUBLIC HEALTH CONCERNS AMONG PEOPLE WHO INJECT DRUGS

---

PWID have multiple health needs that must be addressed in order to support their health and well-being. There are several health issues that are a particular concern to public health, including how the use of drugs can lead to substance use disorder, transmission and acquisition of blood borne pathogens, and deaths due to overdoses.

### **SUBSTANCE USE DISORDER**

PWID have multiple health needs that must be addressed in order to support their well-being. Health issues that are of particular concern to public health include: unhealthy substance use, the acquisition and transmission of life-threatening infections, other serious physical and mental health complications, unsanitary conditions, and overdose death. Using substances by injection increases the risk of harm from substance use.

Unhealthy substance use occurs when it increases a person's risk for health consequences (hazardous use) or has already led to health consequences (harmful use).<sup>3</sup> A substance use disorder (SUD) may be diagnosed when use leads to clinically significant distress and impairment in four broad areas: unhealthy use, social problems, loss of control, and pharmacological symptoms (e.g., tolerance and withdrawal). SUD severity can be mild (2-3), moderate (4-5), or severe (>5) based on the number of diagnostic criteria (out of 11), which an individual experiences in a 12-month period.<sup>4</sup> Many persons with moderate to severe SUD suffer from the disease of addiction.

According to the short definition of “addiction” by the American Society of Addiction Medicine:

*“Addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by substance use and other behaviors.*

*Addiction is characterized by inability to consistently abstain, impairment in behavioral control, craving, diminished recognition of significant problems with one's behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature death.”<sup>5</sup>*

Injecting drugs on the streets is also harmful to PWID due to the potential exposure to communicable diseases and other unsanitary conditions.

## HUMAN IMMUNODEFICIENCY VIRUS (HIV)


People who inject drugs account for 21 percent of people living with HIV in San Francisco. Overall, both diagnoses of HIV infection and HIV related deaths in San Francisco have seen major decreases. Figure 2 shows the trend in PWID newly diagnosed with HIV infection from 2006-2015.<sup>6</sup> Data for the Medical Monitoring Project found that among patients receiving HIV care, 8.1 percent reported injecting drugs in the prior 12 months. Among both newly diagnosed people and people already living with HIV, PWID are less likely to be virally suppressed than the overall populations living with HIV. Viral suppression reduces the likelihood of HIV transmission.

Despite overall declines in the number of newly diagnosed HIV infections among PWID, people newly diagnosed with HIV who are also homeless in San Francisco are much more likely to be PWID. In 2015, SFPDPH reported that PWID have the lowest viral suppression among living people living with the virus. PWID also have the lowest five-year survival out of all others living with HIV, 83 percent compared to 93 percent among men who have sex with men (MSM) who do not inject drugs.<sup>7</sup>

## HEPATITIS C VIRUS (HCV)

The Hepatitis C Virus (HCV) is also a major public health concern in San Francisco. Until recently, limited epidemiological data has inhibited the health department's ability to understand the local epidemic. Mandated laboratory reporting of HCV began in July 2007, and, since then, more than 16,000 people with past or present HCV infections have been reported to the SFPDPH. However, HCV transmission risk is not yet reportable, highlighting a need to better understand how HCV is transmitted through communities in San Francisco. End Hep C SF is a multi-sector collective impact initiative aiming to eliminate the virus in San Francisco. End Hep C SF estimates that there are 23,000 residents who have antibodies to HCV and that approximately 70 percent of active HCV infections are among PWID.<sup>8</sup>

**FIGURE 2: PWID YEAR OF INITIAL HIV DIAGNOSIS**






**OVERDOSE**

While drug injection is a known risk factor for opioid overdose, and most opioid overdose deaths are believed to involve injection of the causal drug, mortality data does not easily establish the role of injection in a death. From 2006-2012, a review of medical examiner records shows that at least 42 percent of opioid deaths during this period were due to heroin, had evidence of drug injection on the scene, or occurred among persons with a history of heroin use or drug injection.

Among 1,758 unintentional opioid or stimulant deaths from 2005-2015 that had geographic information regarding place of death, the largest percentage of deaths (approximately 33%) occurred in the Tenderloin and South of Market, and most of these occurred in single room occupancy hotel units where people tend to use in isolated settings.

Following a substantial reduction in opioid overdose mortality in the early 2000s, overdose deaths from opioids and stimulants in San Francisco have been fairly stable since 2006 (range 164-207 per year). In more recent years, the number of deaths due to opioid analgesics has been declining, while deaths due to heroin have been increasing (to 41 in 2016); there has also been a more recent increase in fentanyl deaths.<sup>9</sup> Deaths due to methamphetamine have increased substantially during this time, whereas deaths due to cocaine have slowly declined. Figure 3 shows the number of drug overdose deaths by drug type over the last decade.<sup>10</sup>

**FIGURE 3: DRUG OVERDOSE DEATHS IN SAN FRANCISCO (2006-2016)**



# SECTION IV

## HARM REDUCTION IN SAN FRANCISCO

---

San Francisco's continuum of substance use disorder services are based on the principles of harm reduction. Harm reduction is a public health philosophy that promotes methods of reducing the physical, social, emotional, and economic harms associated with drug and alcohol use and other harmful behaviors that impact individuals and their community. Harm reduction methods and treatment goals are free of judgment or blame and directly involve clients in setting their own health goals.

### **GUIDING PRINCIPLES OF HARM REDUCTION SERVICES**

- Clients are responsive to culturally competent, non-judgmental services, delivered in a manner that demonstrates respect for individual dignity, personal strength, and self-determination.
- Service providers are responsible to the wider community for delivering interventions which attempt to reduce the economic, social, and physical consequences of drug- and alcohol-related harm and harms associated with other behaviors or practices that put individuals at risk.
- Because those engaged in unsafe health practices are often difficult to reach through traditional service venues, the service continuum must seek creative opportunities and develop new strategies to engage, motivate, and intervene with potential clients.
- Comprehensive treatments need to include strategies that reduce harm for those clients who are unable or unwilling to modify their unsafe behavior.

- Relapse or periods of return to unsafe health practices should not be equated with or conceptualized as “failure of treatment”.
- Each program within a system of comprehensive services can be strengthened by working collaboratively with other programs in the system.
- People change in incremental ways and must be offered a range of treatment outcomes in a continuum of care, from reducing unsafe practices to abstaining from dangerous behavior.

### **SYRINGE ACCESS**

The City and County of San Francisco formally sanctioned syringe access in 1993, when Mayor Frank Jordan declared a public health state of emergency. This gave Mayor Jordan the power to legalize syringe programs, and the City began funding programs as an essential structural component of HIV prevention services. Cities that were early adopters of syringe access had significantly lower rates of HIV infection among PWID than cities that did not address this health need.<sup>11</sup> Local progress and advancements in policies for syringe access have resulted in California and the federal government allowing funds to be used for costs associated with operating a syringe services without having to declare a state of emergency.

A San Francisco study showed that from December 1986 through June 1992, San Francisco syringe programs reduced drug use and drug-related harms. Injection frequency among PWIDs in the community decreased from 1.9 injections per day to 0.7, and the percentage of new individuals initiating injection drug use decreased from 3 percent to 1 percent.<sup>12</sup>

Moreover, this same study found that the syringe access services did not increase drug use among PWID. Additional studies have also found use of syringe services to be associated with reduced syringe sharing and other injection-related risk reduction behaviors.<sup>13,14</sup>

The California legislature has also removed barriers to the purchasing of sterile syringes in pharmacies in the state. In 2004, SB 1159 (Vasconcellos), was passed establishing a five-year pilot program in select counties to allow pharmacies, when authorized by a local government, to sell up to 10 syringes to adults without a prescription. In 2011, the passage of SB 41 (Yee), authorized a county or city to allow licensed pharmacist across the entire state to sell or furnish 10 or fewer hypodermic needles or syringes to a person 18 or older without a prescription. Assembly Bill 1743 (Ting) further expanded this in 2014 to allow for unlimited number of syringes that could be purchased without a prescription.

## **TREATMENT ON DEMAND**

In 1997, SFPDPH launched its *Treatment on Demand* initiative to increase the availability of publicly-funded substance use disorder treatment, including medication-assisted treatment.

Medication-assisted treatment is a harm reduction approach that combines behavioral therapy and medications to treat substance use disorders.<sup>15</sup> Methadone and buprenorphine are two of the main drugs used for medically supervised opioid withdrawal and to treat opioid use disorders. Methadone treatment must be dispensed by a SAMHSA-certified opioid treatment program that are approved by federally-approved agencies.<sup>16</sup> It is taken orally and relieves withdrawal, blocks cravings, and prevents euphoria if other opioids are used.<sup>17</sup>

Buprenorphine treatment occurs in three phases (Induction, Stabilization, and Maintenance) and can be prescribed or dispensed in a physician's office. It is taken daily by mouth or under the skin and alleviates the symptoms of physical withdrawal, reduces or eliminates opioid craving, and partially or completely blocks the euphoric effects of outside opioids. <sup>18,19</sup>

Today, methadone and buprenorphine are a part of the City's medication assisted treatment for opioid addiction, and are available on-demand for people who want to stabilize their illness. Additionally, the City's Homeless Outreach Team has embedded street medicine specialists who initiate medication-assisted treatment and treat abscesses and injection wounds. All of these programs provide linkages to medical care and treatment services.

## **NALOXONE**

In 2003, San Francisco became the first city in the US to use public funds to make naloxone, a medication designed to rapidly reverse opioid overdose, readily available to members of the public, drastically reducing the number of overdose deaths from injection drug use. These efforts began with the leadership of the Harm Reduction Coalition's Drug Overdose Prevention and Education (DOPE) Project. In December 2001, the DOPE Project began piloting training of community and government partners on the recognition, management, response, and prevention of overdoses. In 2003, with the results of the successful pilot, SFPDPH expanded this training and also began to provide prescriptions for naloxone.

In 2008, the California legislature also began to remove the policy limitations on the prescriptions of naloxone. Since then, several bills have been passed to expand access to the drugs used to reverse an overdose as well as who can legally administer the opioid antidote. Due to the widespread availability of naloxone, in 2016, there were 877 reported reversals of overdoses by persons who use drugs who have been trained by community partners in San Francisco.

# SECTION V

## ABOUT SAFE INJECTION SERVICES

---

### BACKGROUND

Safe injection services, part of the continuum of harm reduction services, were developed to promote safer drug injection practices, enhance health-related behaviors among PWID, and connect PWID with external health and social services. Globally, different terms are used to describe the facilities that provide safe injection services: Supervised Injection Facilities (SIFs), Safe Consumption Facilities (SCFs), Drug Consumption Rooms (DCRs), and Supervised Consumption Services (SCS). According to the European Monitoring Centre for Drugs and Drug Addiction, these facilities are “professionally supervised facilities where drug users can consume drugs in safer conditions. They seek to attract hard-to-reach populations of drug users, especially marginalized groups and those who use drugs on the streets or in other risky and unhygienic conditions. One of their primary goals is to reduce morbidity and mortality by providing a safe environment for more hygienic drug use and by training clients in safer drug use. At the same time, they seek to reduce drug use in public and improve public amenity in areas surrounding urban drug markets. A further aim is to promote access to social, health and drug treatment facilities.”<sup>20</sup>

### SAFE INJECTION SERVICES AROUND THE WORLD

Data are available on 10 countries that provide SIS.

- 1) Eight countries (Netherlands, Germany, Spain, Switzerland, Denmark, Canada, France, and Norway) reported having multiple locations (ranging from two to 31) with varying services at each.<sup>21</sup> Spain and Denmark each reported having one mobile drug consumption room in addition to fixed sites. Norway and

Switzerland reported restricting eligibility to person 18 years or older, while Spain and the Netherlands reported that eligibility differed based on the location.

In recent years, the Netherlands, Switzerland, and Spain have closed drug consumption rooms either due to cost, or as a result of reductions in drug use and the associated need for these services.<sup>22</sup>

- 2) Two countries (Australia and Luxemburg) reported having only one location.<sup>23</sup> These countries restrict eligibility to person 18 years or older. All are in fixed locations using an integrated model with a mix of services and linkages to other community services.

#### ***Australia, Canada, Germany, Luxembourg, the Netherlands, Norway, Spain, and Switzerland***

In 2012 the International Drug Policy Consortium released a briefing paper entitled *Drug consumption rooms. Evidence and practice*.<sup>24</sup> The data for the report were provided by staff from each of the safe injection services sites around the world. They noted that Australia, Canada, Luxembourg, the Netherlands, Norway, and Spain were able to provide country-wide data for the report. For Germany and Switzerland, only regional or local data were available. The report provides a profile of each of the eight countries featured.

Table 3 is adapted from the report with the updated number of locations in each country through June 2017 based on the most recent available data. The table also provides a summary of the report’s findings.

**TABLE 3: WORLD OVERVIEW OF DRUG CONSUMPTION ROOMS**

COUNTRY	DCR	ELIGIBILITY & SERVICES	CLIENT PROFILES	RESULTS
<b>Australia</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 1 in Sydney</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• 1 in injecting room</li> <li>• Training: At least 1 nurse, 3 officers with health training</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• 18 years and over</li> <li>• Already drug dependent</li> <li>• Not pregnant nor with child</li> <li>• Not intoxicated</li> <li>• No dealing of drugs on premises</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• Stage 1: Waiting room/assessment area</li> <li>• Stage 2: Injecting room with 8 booths</li> <li>• Stage 3: After care room</li> <li>• Resuscitation room</li> <li>• Links to health, legal, housing, welfare services</li> </ul>	<ul style="list-style-type: none"> <li>• 12,050 clients between May 2001 and April 2010</li> <li>• 3 new clients a day on average</li> <li>• 74% men / 26% women</li> <li>• 33 years of age on average</li> <li>• 13 years of average time injecting</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>• Drop in heroin use (40% in 2005)</li> <li>• Increase in other opioid use (60% in 2012)</li> <li>• Decline in cocaine use (15% in 2012)</li> <li>• 10% methamphetamines</li> <li>• 1-2% buprenorphine</li> </ul>	<ul style="list-style-type: none"> <li>• Cost-effective</li> <li>• Contacts vulnerable groups –</li> <li>• 9,500 referrals to health and social welfare services</li> <li>• 4,400 overdose interventions (no fatalities)</li> <li>• Reduced risk of blood-borne virus transmission</li> <li>• Reduced public injecting and injection-related litter</li> <li>• No adverse impact on local community (e.g. increase in drug-related crime in area)</li> </ul>
<b>Canada</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 2 in Vancouver called 'InSITE'</li> <li>• 3 in Montreal<sup>25</sup></li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• 9 staff</li> <li>• Training: nurses, program workers (PHS), peer support workers</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• No admission criteria</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• Low-threshold, anonymous service with 12 drug consumption booths</li> <li>• Supply of clean injection equipment</li> <li>• Safer use counselling</li> <li>• Primary healthcare services</li> <li>• Voluntary detox (Onsite)</li> <li>• Links to longer-term drug dependence treatment programs</li> <li>• Links to housing and community support</li> </ul>	<ul style="list-style-type: none"> <li>• 1.8 million visitors since 2003</li> </ul> <p>Between 1<sup>st</sup> Jan 2010- 31<sup>st</sup> Dec 2010:</p> <ul style="list-style-type: none"> <li>• 312,214 visits by 12,236 clients</li> <li>• 855 average daily visits</li> <li>• 587 average daily injections</li> <li>• 74% men / 26% women</li> <li>• 17% identified as Aboriginal</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>• 36% heroin</li> <li>• 32% cocaine</li> <li>• 12% morphine</li> </ul>	<ul style="list-style-type: none"> <li>• 221 overdose interventions (no fatalities)</li> <li>• 3,383 clinical treatment interventions</li> <li>• 5,268 referrals to other social and health services</li> <li>• 458 admissions to Onsite detox program (completion rate in 2010: 43%)</li> <li>• Reduced risk of blood-borne virus transmission</li> <li>• Reduced public injecting and injecting-related litter</li> <li>• No adverse impact on local community</li> </ul>

**TABLE 3: WORLD OVERVIEW OF DRUG CONSUMPTION ROOMS**

COUNTRY	DCR	ELIGIBILITY & SERVICES	CLIENT PROFILES	RESULTS
<b>Germany</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 24 in 15 cities country-wide</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• Number of staff variable according to size of DCR and financial constraints</li> <li>• Training: Doctors, nurses, educators, qualified student assistants and freelancers</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• Age eligibility varies according to state regulation</li> <li>• Already drug dependent</li> <li>• Not under OST (except in Hamburg)</li> <li>• Not intoxicated</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• DCRs integrated with harm reduction facilities</li> <li>• Open between 3.5 and 12 hours a day</li> <li>• 3 to 20 drug consumption booths</li> <li>• Links to medical and social services</li> </ul>	<ul style="list-style-type: none"> <li>• In Frankfurt from 2003 to 2009: Up to 4,700 visitors per year</li> <li>• 26-35 years of age on average</li> <li>• 85% men / 15% women</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>• 82% heroin</li> <li>• 36% crack</li> </ul>	<ul style="list-style-type: none"> <li>• Since 1994, no drug-related deaths recorded in Germany</li> <li>• Increased client awareness of safer use techniques</li> <li>• Less drug-related health problems (e.g. fewer abscesses)</li> <li>• Data from North Rhine Westphalia (2001-2009): 3,271 drug emergency cases 710 CPRs</li> </ul>
<b>Luxembourg</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 1 in the City of Luxembourg called 'Abrigado'</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• 23 multilingual staff</li> <li>• Training: Medical staff, psychologists social workers, educators, sociologists</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• 18 years and over</li> <li>• Already drug dependent</li> <li>• Not under OST</li> <li>• Not pregnant or with child</li> <li>• Not intoxicated</li> <li>• No dealing of drugs on premises</li> <li>• Sign a 'terms of use' contract</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• Integrated in low-threshold center with 7 injection booths</li> <li>• Pilot project 'Blow room' with 3 inhalation booths</li> <li>• Open 6 days a week, 6h a day)</li> <li>• Night shelter (42 beds) and nursery Drop-in center (Kontakt Café) with primary medical care</li> <li>• On-site HIV/hepatitis C testing</li> <li>• Needle exchange Program</li> <li>• Safer use counselling</li> </ul>	<ul style="list-style-type: none"> <li>• 170,000 supervised drug consumptions (since 2005)</li> <li>• 26,929 visits to DCR in 2011</li> <li>• 207 average visitors per day (Kontakt Café)</li> <li>• 96 average visitors per day (DCR)</li> <li>• 25-34 years of age on average</li> <li>• 80% men / 20% women</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>• 87% heroin</li> <li>• 8% cocaine</li> <li>• 5% mixtures</li> </ul>	<ul style="list-style-type: none"> <li>• 1,025 overdoses successfully managed (no fatalities)</li> <li>• General decrease in overdose deaths and proportion of people who inject drugs in newly diagnosed HIV infection cases since the opening of the DCR</li> <li>• Citizens hotline established to encourage public acceptance of DCR</li> <li>• A few complaints from neighboring communities recorded</li> </ul>

**TABLE 3: WORLD OVERVIEW OF DRUG CONSUMPTION ROOMS**

COUNTRY	DCR	ELIGIBILITY & SERVICES	CLIENT PROFILES	RESULTS
<b>The Netherlands</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 31 in 25 cities country-wide</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• 3 staff members</li> <li>• Training: Medical staff, social workers, former drug users, security staff</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• Registered in city where DCR is located</li> <li>• Sign a 'terms of use' contract</li> <li>• No dealing of drugs on premises</li> <li>• Different admission criteria according to each DCR</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• 5 'stand-alone' DCRs, others are integrated within low-threshold services</li> <li>• Separate rooms for injectors and smokers</li> <li>• 15 booths for smokers, 5 for injectors</li> <li>• Medical</li> <li>• safer use counselling</li> </ul>	<ul style="list-style-type: none"> <li>• 24 clients per day on average</li> <li>• 90% clients are non-injectors</li> <li>• 45 years of age on average</li> <li>• 90% men / 10% women</li> </ul> <p><b>Principal Substances used</b></p> <ul style="list-style-type: none"> <li>• Heroin</li> <li>• Crack/coke base</li> </ul>	<ul style="list-style-type: none"> <li>• Decrease in needle sharing Only 4% of new diagnoses of HIV, Hepatitis B and C among people who use drugs</li> <li>• HIV incidence rates among people who inject drugs dropped from 8.6% in 1986 to 0% in 2000</li> <li>• 94 acute drug-related deaths in 2010 with 20 non-municipal registered people</li> <li>• Significant decrease in public disturbance</li> <li>• High acceptance of DCRs (80%) by social/health providers, neighborhoods and police</li> </ul>
<b>Norway</b>	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>• 2 in two cities</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>• Minimum of 5 staff on duty during opening hours, including at least 1 Nurse.</li> <li>• Training: Nurses, auxiliary nurses and social workers</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>• Heroin only substance allowed</li> <li>• 18 years and over</li> <li>• Sign a 'terms of use' contract</li> <li>• Long term history of injecting heroin</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>• Limited to one dose of heroin per client per visit</li> <li>• Integrated with harm reduction services</li> <li>• Links with social and health services</li> <li>• Links to drug dependence treatment programs</li> </ul>	<ul style="list-style-type: none"> <li>• 2,480 registered clients since 2005</li> <li>• 1,500 clients per year</li> <li>• 109 clients per day on average (2011)</li> <li>• 37 years of age on average</li> <li>• 70% men / 30% women</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>• Heroin is the only substance allowed to be used in the DCR</li> </ul>	<ul style="list-style-type: none"> <li>• Reduced perception of social exclusion among the user group</li> <li>• Increased access to professional assistance in overdose situations</li> <li>• Increased access to health and social services</li> </ul>

**TABLE 3: WORLD OVERVIEW OF DRUG CONSUMPTION ROOMS**

COUNTRY	DCR	ELIGIBILITY & SERVICES	CLIENT PROFILES	RESULTS
Spain	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>13 in 7 cities country-wide, including 1 mobile DCR</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>Number of staff variable according to each DCR</li> <li>Training: multidisciplinary, with at least 1 nurse</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>18 years and over</li> <li>Sign a 'terms of use' contract (in the Barcelona DCRs)</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>3 DCRs allow smoking</li> <li>Links to social and health services</li> <li>Links to drug dependence treatment programs</li> <li>In Barcelona: HIV testing and counselling, health care and social, psychological and legal support</li> </ul>	<ul style="list-style-type: none"> <li>105,804 visits from 5,063 clients (2009)</li> <li>34 years of age on average</li> <li>80% men / 20% women</li> </ul> <p><b>Principal substances used</b></p> <ul style="list-style-type: none"> <li>Cocaine most popular (except in Bilbao and Sala Balaurd in Barcelona, 2009)</li> <li>Heroin most popular (Barcelona, 2011)</li> <li>Speedball most popular (Madrid, 2011)</li> </ul>	<ul style="list-style-type: none"> <li>Decrease in overdose deaths from 1,833 in 1991 to 773 in 2008</li> <li>Decrease in new HIV infections among clients from 19.9% in 2004 to 8.2% in 2008</li> <li>High acceptance and demand for DCRs</li> <li>Reduced injection-related litter in public spaces</li> <li>Community awareness about DCRs as a public health strategy</li> <li>Development of common guidelines on harm reduction and DCRs</li> </ul>
Switzerland	<p><b>Location</b></p> <ul style="list-style-type: none"> <li>12 in 8 cities country-wide</li> </ul> <p><b>Staff</b></p> <ul style="list-style-type: none"> <li>No country-wide data</li> </ul> <p>In Berne</p> <ul style="list-style-type: none"> <li>Training: nurses and social workers.</li> </ul>	<p><b>Eligibility</b></p> <ul style="list-style-type: none"> <li>18 years and over Already drug dependent</li> <li>Have official documentation</li> <li>No dealing of drugs on premises</li> <li>No consumption tolerated outside the DCR itself (e.g. cafeteria, toilets)</li> </ul> <p><b>Services</b></p> <ul style="list-style-type: none"> <li>Booths for intravenous use, smoking and sniffing (numbers vary according to the DCR)</li> <li>Cafeteria with food and non-alcoholic beverages</li> <li>Medical treatment</li> <li>Consultations for social problems</li> <li>Hygiene services (showers, provision of clothes)</li> <li>NSP</li> <li>Links to drug dependence treatment programs and clinics</li> </ul>	<ul style="list-style-type: none"> <li>No country-wide data</li> </ul> <p>In Berne:</p> <ul style="list-style-type: none"> <li>38 years of age on average</li> <li>992 registered clients a year</li> <li>200 clients a day</li> <li>74.1% men / 25.9% women</li> </ul> <p><b>Principal Substances Used</b></p> <ul style="list-style-type: none"> <li>No country-wide data</li> </ul> <p>In Berne: Heroin Cocaine</p> <ul style="list-style-type: none"> <li>Benzodiazepines</li> <li>Cannabis Substitutes</li> <li>Alcohol</li> </ul>	<ul style="list-style-type: none"> <li>Decrease in drug-related deaths</li> <li>Increased client awareness of safer use techniques</li> <li>Reduces risk of blood-borne virus transmission</li> </ul>



### **Denmark and France**

In addition to the findings from the countries profiled in the table above, experience from Denmark and France provide further information. Denmark has five facilities currently operating. Four are fixed sites using an integrated model, typically part of a shelter with additional services such as counselling, laundry and shower facilities and a health clinic. These sites are financed through provisional governmental funds and managed by non-governmental organizations. Denmark also has one mobile DCR, which is directly financed and run by the Municipality of Copenhagen.<sup>26</sup> France launched two drug injection facilities in 2016 as part of their 6-year national strategy to address the spread of infection and drug overdoses.<sup>27</sup>

### **Belgium, Ireland, Scotland, and Slovenia**

Slovenia recently revised their penal code to allow for the opening of supervised consumption facilities, and a planned pilot project is pending. HIV outbreaks among PWID in Scotland and Ireland have led to discussions about the introduction of supervised drug consumption facilities. In 2016, Belgium initiated a study to explore the feasibility of drug consumption facilities in five major cities in Belgium.<sup>28</sup>

### **Massachusetts, New York, Maine, Seattle, and King County, WA**

While SIS are not yet legal in the US, at least several states are exploring legislation similar to California's that would remove prohibitions on operating SIS and allow for pilot projects, including Massachusetts, New York, and Maine.<sup>29, 30, 31</sup>

In January 2017, officials in Seattle and King County, Washington approved opening safe consumption facilities in their jurisdiction. The development of pilot "Community Health Engagement Locations" were recommended by the Heroin and Prescription Opiate Addiction Task Force Final Report released in September 2016. In preparation for the facilities, the County developed a document entitled *Safe Consumption Facilities: Evidence and Models*.<sup>32</sup> The document provides a review of the different services and delivery models. Models differ in staffing, size and organizational structure. Features and staffing levels are based on local circumstances.

The document summarizes three basic models that they refer to as Integrated, Specialized, and Mobile. Information in Table 4 below is taken directly from the report and provides a summary of each of the models and some of the key advantages and disadvantages that were identified.

While the recommendation has support from the Mayor, health department and other key stakeholders, it has recently been met with major opposition by some members of the community who are seeking to pass an initiative to ban heroin injection sites in King County.<sup>33</sup> Washington State Senator Mark Miloscia, supports the ballot initiative and has written a letter to Attorney General Jeff Sessions urging him to intervene and asserting that if a site is allowed to open in King County "they will continue to spread to other parts of our state, and eventually to other communities across our nation."<sup>34</sup>

**TABLE 4: DESCRIPTION OF SAFE CONSUMPTION FACILITY (SCF) MODELS AND SOME OF THE KEY ADVANTAGES AND DISADVANTAGES THAT WERE IDENTIFIED**

<b>MODEL</b>	<b>DESCRIPTIONS</b>	<b>KEY ADVANTAGES AND DISADVANTAGES</b>
<b>Integrated</b>	Integrated SCFs are the most common type. The SCF is part of a broader and interlinked network of services housed in the same facility. Examples of services offered include: drop-in center with showers and laundry facilities, counseling and testing for blood borne viral infections, needle and syringe exchange, psychosocial care, employment programs, medical services, wound care, medication-assisted treatment.	<p><b>Advantages:</b> “One-stop-shop” offers convenient access to other important health and social services; consistent with current emphasis on offering integrated and coordinated care for persons with complex medical conditions.</p> <p><b>Disadvantages:</b> Integrating a drug consumption space with medication-assisted treatment (MAT) places a burden on individuals picking up their medication. These individuals may be trying to stay away from areas of active drug use; complexity, cost.</p>
<b>Specialized</b>	Specialized SCFs focus on providing a safe place for hygienic consumption of drugs in a non-judgmental environment, while providing referrals to other services. The SCF is usually located in close proximity to other services and near an open-air drug market.	<p><b>Advantages:</b> Single focus requires less operational complexity. Referrals to other services are available, just not in house; less expensive to site and operate than more comprehensive models.</p> <p><b>Disadvantages:</b> Access to additional services is not as convenient as an integrated model, creating a potential barrier to accessing services.</p>
<b>Mobile</b>	Mobile SCFs are specially outfitted vans that provide space for 1-3 injection booths inside. They offer a limited range of other services such as syringe and needle exchange and blood borne virus testing and are able to provide referrals to other services not available directly on the van.	<p><b>Advantages:</b> Able to reach populations outside the service range of stationary SCFs.</p> <p><b>Disadvantages:</b> Low throughput capacity, limited services offered.</p>

Note: Adapted from Wright, N. M. (2004). Supervised injecting centres. *British Medical Journal*, 328(7431), 100-102. doi:10.1136/bmj.328.7431.100

# SECTION VI

## POTENTIAL BENEFITS & RISKS OF SAFE INJECTION SERVICES

---

### **BENEFITS**

Potier and colleagues conducted a systemic review of seventy-five articles that were published on these facilities. “The article found that SIS were effective in attracting the most marginalized PWID, promoting safer injection conditions, enhancing access to primary health care, and reducing the overdose frequency. SIS were not found to increase drug injecting, drug trafficking or crime in the surrounding environments. SIS were found to be associated with reduced levels of public drug injections and dropped syringes. Of the articles, 85 percent originated from Vancouver or Sydney.”<sup>35</sup>

In 2002, Brodhead and colleagues published a comprehensive evaluation of the operations and benefits of Safe Injection Facilities (SIFs). The authors visited 19 SIFs in Germany, Switzerland, the Netherlands and Sydney, Australia. Based on their findings, the authors concluded:

“Our review suggests that SIFs target several public health problems that municipalities in North America may wish to consider, problems largely unaddressed by needle exchange, street-outreach, education campaigns, HIV counseling, and other conventional services. SIFs target injectors’ use of public spaces to inject drugs in order to reduce the many risks associated with the practice. Compared to conventional services, SIFs provide greater opportunities for health workers to connect with injectors, and to move them into primary care, drug treatment, and other rehabilitation services. Finally, SIFs target the ‘nuisance factor’ of drug scenes -- the hazardous litter and intimidating presence

of injectors congregating in city parks, public playgrounds and on street corners -- by offering them an alternative, supervised ‘public’ space. Our review also suggests that, for municipalities considering SIFs in order to address these problems, their implementation would not necessarily require any significant or fundamental changes in public policy or law: SIFs require the same working agreements with social service providers and the police that needle exchange, street-outreach, drug treatment and similar health programs for injectors already receive.”<sup>36</sup>

### **COST BENEFIT**

#### ***San Francisco***

In 2017, Amos Irwin and colleagues published an article titled *A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA*.<sup>37</sup> Using a number of studies and local health data, the researchers developed a mathematical model to create an estimate of the financial cost and benefits that a SIS can provide to San Francisco. The researchers found that each dollar spent on SIS would generate \$2.33 in savings, for total annual net savings of \$3.5 million for a single 13-booth SIS site. They further found that a SIS site in San Francisco would not only be a cost-effective intervention but also a significant boost to the public health system.

They first developed an estimation of the cost of operating a facility based on the Vancouver program InSITE. They estimate that it would cost San Francisco \$2.6 million annually to operate a similar facility. They also acknowledged SFDPH

**TABLE 5: HEALTH CONDITIONS AND THE POTENTIAL HEALTH BENEFIT AND SAVINGS**

HEALTH CONDITION	POTENTIAL HEALTH BENEFIT AND SAVINGS
<b>HIV</b>	A prediction that one site would help avert 3.3 HIV cases per year, with a lifetime treatment cost of over \$402,000, this translates to annual savings of \$1.3 million.
<b>HCV</b>	A prediction that one site would help prevent 19 cases per year, with a lifetime cost of \$68,000, this translates to annual savings of \$1.3 million.
<b>Skin and Soft Tissue Infection</b>	A prediction that one site would reduce hospital stays by 415 days per year, which translates to savings of roughly \$1.7 million.
<b>Overdose prevention</b>	A prediction that one site with overdose prevention services will save an average of 0.24 lives per year, which translates to \$284,000 in financial benefit.
<b>Medication-Assisted Treatment</b>	A prediction that one site would assist 110 PWID to enter treatment, resulting in an annual financial benefit of \$1.5 million.

Note: Summary from Irwin, A., Jozaghi, E., Bluthenthal, R. N., & Kral, A. H. (2017). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, 47(2), 164-184. doi:10.1177/0022042616679829

would need to reevaluate the cost associated with operating a facility based on the model and protocols prioritized by the department.

Table 5 is a summary of the benefits and savings identified in the article. It is important to also note that the estimation of health benefits and costs are based on providing this as an additional service over and above the current levels of services offered in the San Francisco, not replacing existing services. In personal communication with one of the co-authors, he also noted that the predication of the financial benefits for overdose prevention may also be under-estimated as the calculation of the savings was conducted a few years ago when the overdoses were at the lowest levels in San Francisco.

**Vancouver, Canada**

In 2008, researchers in Canada conducted a study on the cost-effectiveness of the Canadian supervised injection facility. InSITE is North America’s first legal supervised injection site that was opened in 2003 by Vancouver Coastal Health. Below is an excerpt from the study published in the Canadian Medical Association Journal.

**"Results:** Focusing on the base assumption of decreased needle sharing as the only effect of the supervised injection facility, we found

that the facility was associated with an incremental net savings of almost \$14 million and 920 life-years gained over 10 years. When we also considered the health effect of increased use of safe injection practices, the incremental net savings increased to more than \$20 million and the number of life-years gained to 1,070. Further increases were estimated when we considered all 3 health benefits: the incremental net savings was more than \$18 million and the number of life-years gained 1,175."<sup>38</sup>

**RISKS**

**Federal and State Controlled Substances Laws**

Currently, the possession of controlled substances, unless the possession is with the prescription of a licensed health professional, is prohibited by both state and federal law. State and federal law also prohibits building owners and operators from allowing the manufacturing, storing, or distributing controlled substances.

Specifically, at the federal level, there are two major statutory considerations under Title 21 of the United States Code (USC) Controlled Substance Act (CSA) that need to be taken into account when discussing the operations of a SIS in San Francisco. Under section 844 (c) of the CSA, the term “Drug, narcotic, or chemical offense is

defined: drug, narcotic, or chemical offense means any offense which proscribes the possession, distribution, manufacture, cultivation, sale, transfer, or the attempt or conspiracy to possess, distribute, manufacture, cultivate, sell or transfer any substance the possession of which is prohibited under this subchapter.”<sup>39</sup> This means individuals arriving at a SIS, who are bringing their own drugs, would be violating the federal law.

Further, CSA Section 856, ‘Maintaining drug-involved premises’ (also known as the Crack House Statute) states the following under (a) Unlawful acts:

“Except as authorized by this subchapter, it shall be unlawful to—

(1) knowingly open, lease, rent, use, or maintain any place, whether permanently or temporarily, for the purpose of manufacturing, distributing, or using any controlled substance;

(2) manage or control any place, whether permanently or temporarily, either as an owner, lessee, agent, employee, occupant, or mortgagee, and knowingly and intentionally rent, lease, profit from, or make available for use, with or without compensation, the place for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance.”<sup>40</sup>

Section 856 outlines the criminal penalties, violation as offense against property, and civil penalties that may be imposed on all the parties engaged in the property.

These federal laws are enforced by the US Attorney General. On May 12, 2017, Attorney General Jeff Sessions directed all federal prosecutors to pursue the maximum penalties

under the law for all crimes, including mandatory minimum sentences. Most mandatory minimum sentences apply to drug offenses.<sup>41</sup>

Mirroring federal law, California law also prohibits the possession of controlled substances and provides for criminal penalties and fines to the individual(s) that has the illegal substance on their person and also to building owners and operators that allow manufacturing, storing, or distributing controlled substances on their premises.<sup>42</sup> Assembly Bill 186 is currently being considered by the California Legislature to remove the penalties for violation of these laws when associated with the operation of a safe consumption services program authorized by the local government entity.

### **Government Contracting Requirements**

Another risk that has been identified is the standard boiler plate language used in federal, state and local funding agreements regarding maintaining a drug free work place. Please note that this matter is separate from the federal laws under the CSA. Below is an example of language that is part of the boiler plate for Medi-Cal and (i.e., Medicaid) and the federal block grant from the Substance Abuse and Mental Health Services Administration:

#### **“No Unlawful Use or Unlawful Use Messages Regarding Drugs**

Contractor agrees that information produced through these funds, and which pertains to drug and alcohol- related programs, shall contain a clearly written statement that there shall be no unlawful use of drugs or alcohol associated with the program. Additionally, no aspect of a drug or alcohol- related program shall include any message on the responsible use, if the use is unlawful, of drugs or alcohol (HSC Section 11999-11999.3). By signing this Contract, Contractor agrees that it will enforce, and will require its Subcontractors to enforce, these requirements.”<sup>43</sup>

# SECTION VII


## CONSIDERATIONS FOR SAN FRANCISCO REGARDING SAFE INJECTION SERVICES

### LOCATION

A key consideration for implementing SIS is identifying locations where PWID already access services. Research conducted in San Francisco in 2008 found that 85 percent of study participants reported they would use SIS services if they were convenient for them.<sup>44</sup> Researchers further found a correlation between PWID who reported having injected in a public place and their intent to use SIS services. The survey further found that nearly three-quarters of respondents (72%) would be willing to walk up to 20 minutes to a SIS site. Figure 3 depicts locations that PWID suggested for SIS locations. Suggested locations were clustered in the Tenderloin, South of Market, Mission, and Bayview neighborhoods.

These suggested locations correspond with neighborhoods within which PWID reside. Approximately 55 percent of PWID are in 94102 (Tenderloin/Civic Center, 31%) and 94103 (South of Market, 24%). The next highest zip codes are 94110 (Mission, 9%) followed by 94124 (Bayview, 8%). Figure 1 shows the estimated percent of population size by zip codes. While data is available only at the zip code level, PWID populations may cluster in particular corridors within a zip code with limited movement outside those corridors. Thus, placing one SIS location in 94102 may combat public drug use in the blocks surrounding this location, but will likely not impact public use in other areas.

**FIGURE 3: INJECTION DRUG USERS' SUGGESTIONS FOR LOCATIONS OF SAFE INJECTION SERVICES (N=408)**



Source of Data: RTI Urban Health Program, 2008

### COMMUNITY ENGAGEMENT

Engagement of the communities surrounding any proposed SIS location will be critical. One study that conducted in-depth interviews with 20 sampled stakeholders, including representatives from neighborhood and business associations, politicians, law enforcement, religious leaders, school officials, community activists and service providers, found concern about the implementation of SIS.<sup>45</sup> Specifically, stakeholders were concerned about how SIS would impact a community struggling with safety and cleanliness and questioned the efficacy of harm reduction strategies to address drug use. Stakeholders indicated that they were open to dialogue about how a SIS site might support neighborhood goals; and they stressed the importance of respect and collaboration between stakeholders and those potentially implementing SIS. The researcher noted that government protection and political leadership will be necessary to implement a SIS.

## **PROGRAM DESIGN**

The programmatic design of any contemplated SIS location would need to ensure acceptability by and support of PWID. Identifying locations where PWID are already being served, as noted above, is one key element of program design. Additionally, the presence of other onsite support services, the accessibility of services, and the structure of the rules governing the program would also be critical. Of the 85 percent of PWID surveyed in San Francisco who said they would use SIS services if they were convenient for them, over two-thirds reported that they would accept many potential rules and regulations.<sup>46</sup> Three-quarters of respondents said they would use SIS services at least three days per week and the majority (62%) indicated their preferred time of operation would be 8am to 4pm.

Availability of on-site supportive services would be essential to promoting recovery and wellness for PWID. SIS integrated with other on-site services and supports is the predominant model of SIS across the world. Research shows that SIS can provide opportunities for health workers to connect PWID to primary care, drug treatment, and other substance use disorder services and that access to such services improve the general health, stability, and level of functioning of PWID.<sup>47</sup>

## **LEGAL**

It will be important for any proposed SIS provider to fully understand the associate legal risks. While legislation is currently pending to address some of the state-level risks, federal legal risks remain.

# SECTION VIII

## CONCLUSION

---

This issue brief provides background information and highlights important policy considerations to support the SIS Task Force as it develops its recommendations to the Mayor, the Board of Supervisors, and City Departments in accordance with Board of Supervisors Resolution #123-17.



# ENDNOTES

---

- <sup>1</sup> Chen, Y., Mcfarland, W., & Raymond, H. F. (2015). Estimated Number of People Who Inject Drugs in San Francisco, 2005, 2009, and 2012. *AIDS and Behavior*, 20(12), 2914-2921. doi:10.1007/s10461-015-1268-7
- <sup>2</sup> Chen, Y., Mcfarland, W., & Raymond, H. F. (2015). Estimated Number of People Who Inject Drugs in San Francisco, 2005, 2009, and 2012. *AIDS and Behavior*, 20(12), 2914-2921. doi:10.1007/s10461-015-1268-7
- <sup>3</sup> American Society of Addiction Medicine (2013). Terminology Related to the Spectrum of Unhealthy Substance Use. Retrieved from <https://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2014/08/01/terminology-related-to-the-spectrum-of-unhealthy-substance-use>
- <sup>4</sup> Hasin, D.S. et al. (2013). DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. *American Journal of Psychiatry*, 170(8), 834-851. Retrieved from <http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2013.12060782>
- <sup>5</sup> American Society of Addiction Medicine (2011). Definition of Addiction. Retrieved from <https://www.asam.org/quality-practice/definition-of-addiction>
- <sup>6</sup> San Francisco Department of Public Health, Population Health Division - HIV Epidemiology Section. (2016, September). *HIV Epidemiology Annual Report 2015*. Retrieved from <https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2015-20160831.pdf>
- <sup>7</sup> San Francisco Department of Public Health, Population Health Division - HIV Epidemiology Section. (2016, September). *HIV Epidemiology Annual Report 2015*. Retrieved from <https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2015-20160831.pdf>
- <sup>8</sup> Hepatitis C in San Francisco. (n.d.). Retrieved June 5, 2017, from [https://cdn.shopify.com/s/files/1/1376/6245/files/endhepc-prevalence-layperson\\_2pager\\_FINAL\\_2.pdf?6013879903677780765](https://cdn.shopify.com/s/files/1/1376/6245/files/endhepc-prevalence-layperson_2pager_FINAL_2.pdf?6013879903677780765)
- <sup>9</sup> Coffin, P.O. (2017). Opioids and Stimulants in San Francisco [PowerPoint Slides]. San Francisco Department of Public Health.
- <sup>10</sup> Coffin, P.O. (2017). Opioids and Stimulants in San Francisco [PowerPoint Slides]. San Francisco Department of Public Health.
- <sup>11</sup> Hurley, S. F., Jolley, D. J., & Kaldor, J. M. (1997). Effectiveness of needle-exchange programmes for prevention of HIV infection. *The Lancet*, 349(9068), 1797-1800. doi:10.1016/s0140-6736(96)11380-5
- <sup>12</sup> Watters, J.K., Estilo M.J., Clark, G.L., & Lorvick, J. (1994). Syringe and Needle Exchange as HIV/AIDS Prevention for Injection Drug Users. *JAMA: The Journal of the American Medical Association*, 271(2), 115. doi:10.1001/jama.1994.03510260047027

- 
- <sup>13</sup> Bluthenthal, R. N., Kral, A. H., Erringer, E. A., & Edlin, B. R. (1998). Use of an Illegal Syringe Exchange and Injection-Related Risk Behaviors Among Street-Recruited Injection Drug Users in Oakland, California, 1992 to 1995. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 18(5), 505-511. doi:10.1097/00042560-199808150-00013
- <sup>14</sup> Guydish, J., Bucardo, J., Young, M., Woods, W., Grinstead, O., & Clark, W. (1993). Evaluating needle exchange: are there negative effects? *AIDS*, 871-6. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8395856>.
- <sup>15</sup> Substance Abuse and Mental Health Services Administration (n.d.) Medication-Assisted Treatment (MAT). Retrieved from <https://www.samhsa.gov/medication-assisted-treatment>
- <sup>16</sup> Substance Abuse and Mental Health Services Administration (n.d.) Methadone. Retrieved from <https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone>
- <sup>17</sup> Clark, L., Haram, E., Johnson, K. & Molfenter, T. (2010). Getting Started with Medication-assisted Treatment: With lessons from Advancing Recovery. *NIATx*. Retrieved from <https://www.niatx.net/PDF/NIATx-MAT-Toolkit.pdf>
- <sup>18</sup> Substance Abuse and Mental Health Services Administration (n.d.) Buprenorphine. Retrieved from <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>
- <sup>19</sup> Clark, L., Haram, E., Johnson, K. & Molfenter, T. (2010). Getting Started with Medication-assisted Treatment: With lessons from Advancing Recovery. *NIATx*. Retrieved from <https://www.niatx.net/PDF/NIATx-MAT-Toolkit.pdf>
- <sup>20</sup> Guydish, J., Bucardo, J., Young, M., Woods, W., Grinstead, O., & Clark, W. (1993). Evaluating needle exchange: are there negative effects? *AIDS*, 871-6. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8395856>.
- <sup>21</sup> European Monitoring Centre for Drugs and Drug Addiction (2017). Drug consumption rooms: an overview of provision and evidence. *Perspectives on Drugs*. Retrieved from <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
- <sup>22</sup> European Monitoring Centre for Drugs and Drug Addiction (2017). Drug consumption rooms: an overview of provision and evidence. *Perspectives on Drugs*. Retrieved from <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
- <sup>23</sup> European Monitoring Centre for Drugs and Drug Addiction (2017). Drug consumption rooms: an overview of provision and evidence. *Perspectives on Drugs*. Retrieved from <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
- <sup>24</sup> Schatz, E. & Nougier, M. (2012). Drug consumption rooms: evidence and practice. *International Drug Policy Consortium*. Retrieved from [http://www.drugsandalcohol.ie/17898/1/IDPC-Briefing-Paper\\_Drug-consumption-rooms.pdf](http://www.drugsandalcohol.ie/17898/1/IDPC-Briefing-Paper_Drug-consumption-rooms.pdf)
- <sup>25</sup> Laframboise, K. (2017). Montreal's supervised injection sites open, a first in Eastern Canada. *CBC News*. Retrieved from <http://www.cbc.ca/news/canada/montreal/montreal-safe-injection-sites-open-2017-1.4166638>
- <sup>26</sup> Schatz, E. & Nougier, M. (2012). Drug consumption rooms: evidence and practice. *International Drug Policy Consortium*. Retrieved from [http://www.drugsandalcohol.ie/17898/1/IDPC-Briefing-Paper\\_Drug-consumption-rooms.pdf](http://www.drugsandalcohol.ie/17898/1/IDPC-Briefing-Paper_Drug-consumption-rooms.pdf)
-

- 
- <sup>27</sup> European Monitoring Centre for Drugs and Drug Addiction (2017). Drug consumption rooms: an overview of provision and evidence. *Perspectives on Drugs*. Retrieved from <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
- <sup>28</sup> European Monitoring Centre for Drugs and Drug Addiction (2017). Drug consumption rooms: an overview of provision and evidence. *Perspectives on Drugs*. Retrieved from <http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms>
- <sup>29</sup> An Act to authorize public health workers to pursue new measures to reduce harm and stigma for people affected by substance use disorder, Bill S.1081. *The 190<sup>th</sup> General Court of the Commonwealth of Massachusetts* (2017). Retrieved from <https://malegislature.gov/Bills/190/S1081>
- <sup>30</sup> An Act to amend the public health law, in relation to enacting the safer consumption services act, A08534. *New York State Assembly* (2017). Retrieved from [http://nyassembly.gov/leg/?default\\_fld=&leg\\_video=&bn=A08534&term=2017&Summary=Y&Text=Y](http://nyassembly.gov/leg/?default_fld=&leg_video=&bn=A08534&term=2017&Summary=Y&Text=Y)
- <sup>31</sup> An Act to prevent overdose deaths and infectious diseases by establishing safer drug use facilities, LR1375. *128<sup>th</sup> Maine Legislature* (2017). Retrieved from [http://www.mainelegislature.org/legis/bills/bills\\_128th/billtexts/HP095401.asp](http://www.mainelegislature.org/legis/bills/bills_128th/billtexts/HP095401.asp)
- <sup>32</sup> Otter, D., RN. (2016, April 22). *Safe Consumption Facilities: Evidence and Models* (Rep.). Retrieved March 29, 2017, from King County - Heroin and Opiate Addiction Task Force website: <http://www.kingcounty.gov/depts/community-human-services/mental-health-substance-abuse/heroin-opiates-task-force.aspx>
- <sup>33</sup> Ban heroin injection sites in King County. (n.d.). Retrieved June 5, 2017, from <https://safekingcounty.org/keypoints/> Sen. Miloscia Letter to U.S Attorney General Jeff Sessions. (n.d.). Retrieved June 5, 2017, from <http://markmiloscia.src.wastateleg.org/sen-miloscia-letter-u-s-attorney-general-jeff-sessions/>
- <sup>34</sup> Sen. Miloscia Letter to U.S Attorney General Jeff Sessions. (n.d.). Retrieved June 5, 2017, from <http://markmiloscia.src.wastateleg.org/sen-miloscia-letter-u-s-attorney-general-jeff-sessions/>
- <sup>35</sup> Potier, C., Lapr evote, V., Dubois-Arber, F., Cottencin, O., & Rolland, B. (2014). Supervised injection services: What has been demonstrated? A systematic literature review. *Drug and Alcohol Dependence*, 145, 48-68. doi:10.1016/j.drugalcdep.2014.10.012
- <sup>36</sup> Broadhead, R. S., Kerr, T. H., Grund, J. C., & Altice, F. L. (2002). Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. *Journal of Drug Issues*, 32(1), 329-355. doi:10.1177/002204260203200113
- <sup>37</sup> Irwin, A., Jozaghi, E., Bluthenthal, R. N., & Kral, A. H. (2017). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, 47(2), 164-184. doi:10.1177/0022042616679829
- <sup>38</sup> Bayoumi, A. M., & Zaric, G. S. (2008). The cost-effectiveness of Vancouver's supervised injection facility. *Canadian Medical Association Journal*, 179(11), 1143-1151. doi:10.1503/cmaj.080808
- <sup>39</sup> Title 21 United States Code (USC) Controlled Substances Act, Title 21 United States Code (USC) Controlled Substances Act. (n.d.). Retrieved May 16, 2017, from <http://www.deadiversion.usdoj.gov/21cfr/21usc/844.htm>
-

---

<sup>40</sup> Title 21 United States Code (USC) Controlled Substances Act, Part D — Offenses And Penalties. (n.d.). Retrieved May 16, 2017, from <https://www.deadiversion.usdoj.gov/21cfr/21usc/856.htm>

<sup>41</sup> Jeff Sessions's criminal charging policy. (n.d.). Retrieved June 2, 2017, from <http://apps.washingtonpost.com/g/documents/national/jeff-sessions-criminal-charging-policy/2432/>

<sup>42</sup> Health and Safety Code 11377. (n.d.). Retrieved June 5, 2017, from <http://leginfo.legislature.ca.gov/faces/selectFromMultiples.xhtml>

<sup>43</sup> Health and Safety Code - HSC § 11350. (n.d.). Retrieved June 5, 2017, from <http://leginfo.legislature.ca.gov/faces/selectFromMultiples.xhtml?sectionNum=11350&lawCode=HSC>

<sup>44</sup> Kral, A. H., Wenger, L., Carpenter, L., Wood, E., Kerr, T., & Bourgois, P. (2010). Acceptability of a safer injection facility among injection drug users in San Francisco. *Drug and Alcohol Dependence*, 110(1-2), 160-163. doi:10.1016/j.drugalcdep.2010.02.009

<sup>45</sup> Wenger, L. D., Arreola, S. G., & Kral, A. H. (2011). The prospect of implementing a Safer Injection Facility in San Francisco: Perspectives of community stakeholders. *International Journal of Drug Policy*, 22(3), 239-241. doi:10.1016/j.drugpo.2011.01.001

<sup>46</sup> Kral, A. H., Wenger, L., Carpenter, L., Wood, E., Kerr, T., & Bourgois, P. (2010). Acceptability of a safer injection facility among injection drug users in San Francisco. *Drug and Alcohol Dependence*, 110(1-2), 160-163. doi:10.1016/j.drugalcdep.2010.02.009

<sup>47</sup> Broadhead, R. S., Kerr, T. H., Grund, J. C., & Altice, F. L. (2002). Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. *Journal of Drug Issues*, 32(1), 329-355. doi:10.1177/002204260203200113

# APPENDIX C

SUMMARY OF LOCAL SURVEY & INTERVIEW TOOLS


# SURVEY OF PEOPLE WHO INJECT DRUGS

## OVERVIEW

- In-person interviews with PWID in SF (n=40)
- May 23 to June 7, 2017
- 10-20 min surveys in the field
- 3 neighborhoods
  - Tenderloin (13 interviews)
  - Civic Center (12 interviews)
  - South of Market (15 interviews)


## KEY FINDINGS

**Drug Use:** Participants reported they had injected:




## DEMOGRAPHICS


### AGE




### GENDER



### RACE/ETHNICITY







**OVERVIEW**

- PEOPLE IN EARLY RECOVERY (<1 YEAR)
- 96 PARTICIPANTS
- 43% FORMER INJECTION DRUG USERS
- JUN 2017 - JUL 2017
- 13 QUESTIONS: 4 OPEN-ENDED
- 25 NEIGHBORHOODS REPRESENTED


**GENDER**






**RACE / ETHNICITY**



**AGE RANGE**



- SF BUSINESS OWNERS, NEIGHBORHOOD GROUPS, & RESIDENTS
- 565 RESPONSES
- JUN 2017 - JUL 2017
- 14 QUESTIONS: 4 OPEN-ENDED
- 27 ZIP CODES REPRESENTED



- SF BUSINESS OWNERS, NEIGHBORHOOD GROUPS, & RESIDENTS
- 18 PARTICIPANTS
- JULY 2017
- 11 QUESTIONS: 8 OPEN-ENDED
- 9 ZIP CODES REPRESENTED

